The company has also added a group of industry experts to its advisory board.
Douglas most recently led Bridge4Bio, a business consultancy. Prior to this he was managing director and president of Hoefer, a division of Harvard Bioscience.
The new members of the advisory board are Lori Kunkel, who has held various senior positions in the industry, including chief medical officer at Proteolix/Onyx Pharmaceuticals and vice president of clinical development at Xenocor, and Paul Nowak, ceo of Biotix Holdings.
Nowak has spent the majority of his career at VWR International, a global distributor of laboratory supplies, where he held many positions, including ceo and president.
BioCision appoints coo
Also expands corporate advisory board
You may also like
Manufacturing
![Beyond the Vacuum Pump: Is your Vacuum System costing more than you think?]()
Beyond the Vacuum Pump: Is your Vacuum System costing more than you think?
Many facilities continue to rely on oil-lubricated vacuum pumps that were installed years ago. The question is no longer whether these pumps work. The question is whether they remain the most efficient solution for today's operational, environmental and productivity requirements
Manufacturing
![Stevanato Group and Aptar Pharma collaborate to accelerate prefilled syringe system selection]()
Stevanato Group and Aptar Pharma collaborate to accelerate prefilled syringe system selection
Joint system-level testing combines Stevanato's glass syringes with Aptar's elastomer components to provide key data earlier in development and inform packaging decisions for sensitive biologics and other injectable therapies
Manufacturing
![Why CAPA keeps failing and what strong organisations do differently]()
Why CAPA keeps failing and what strong organisations do differently
This white paper examines why CAPA systems often close records without preventing recurrence, tracing breakdowns to investigation quality, risk reasoning, and organisational behaviour rather than procedural gaps. It outlines what differentiates compliant CAPA programmes from those that consistently reduce repeat findings and inspection risk
